Richard F Olsson1, Stefan Hagelberg, Bodil Schiller, Olle Ringdén, Lennart Truedsson, Anders Åhlin. 1. 1 Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Huddinge, Sweden. 2 Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 3 Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden. 4 Department of Paediatrics, Karolinska University Hospital, Stockholm, Sweden. 5 Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Sachs' Children's and Youth Hospital, Stockholm, Sweden. 6 Section of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Abstract
BACKGROUND: Human C1q deficiency is associated with systemic lupus erythematosus (SLE) and increased susceptibility to severe bacterial infections. These patients require extensive medical therapy and some develop treatment-resistant disease. Because C1q is produced by monocytes, it has been speculated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cure this disorder. METHODS: We have so far treated 5 patients with C1q deficiency. In 3 cases, SLE symptoms remained relatively mild after the start of medical therapy, but 2 patients developed treatment-resistant SLE, and we decided to pursue treatment with allo-HSCT. For this purpose, we chose a conditioning regimen composed of treosulfan (14 g/m) and fludarabine (30 mg/m) started on day -6 and given for 3 and 5 consecutive days, respectively. Thymoglobulin was given at a cumulative dose of 8 mg/kg, and graft-versus-host disease prophylaxis was composed of cyclosporine and methotrexate. RESULTS: A 9-year-old boy and a 12-year-old girl with refractory SLE restored C1q production after allo-HSCT. This resulted in normal functional properties of the classical complement pathway followed by reduced severity of SLE symptoms. The boy developed posttransplant lymphoproliferative disease, which resolved after treatment with rituximab and donor lymphocyte infusion. Unfortunately, donor lymphocyte infusion induced severe cortisone-resistant gastrointestinal graft-versus-host disease, and the patient died from multiple organ failure 4 months after transplantation. The girl is doing well 33 months after transplantation, and clinically, all signs of SLE have resolved. CONCLUSIONS: Allo-HSCT can cure SLE in human C1q deficiency and should be considered early in subjects resistant to medical therapy.
BACKGROUND:Human C1q deficiency is associated with systemic lupus erythematosus (SLE) and increased susceptibility to severe bacterial infections. These patients require extensive medical therapy and some develop treatment-resistant disease. Because C1q is produced by monocytes, it has been speculated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cure this disorder. METHODS: We have so far treated 5 patients with C1q deficiency. In 3 cases, SLE symptoms remained relatively mild after the start of medical therapy, but 2 patients developed treatment-resistant SLE, and we decided to pursue treatment with allo-HSCT. For this purpose, we chose a conditioning regimen composed of treosulfan (14 g/m) and fludarabine (30 mg/m) started on day -6 and given for 3 and 5 consecutive days, respectively. Thymoglobulin was given at a cumulative dose of 8 mg/kg, and graft-versus-host disease prophylaxis was composed of cyclosporine and methotrexate. RESULTS: A 9-year-old boy and a 12-year-old girl with refractory SLE restored C1q production after allo-HSCT. This resulted in normal functional properties of the classical complement pathway followed by reduced severity of SLE symptoms. The boy developed posttransplant lymphoproliferative disease, which resolved after treatment with rituximab and donor lymphocyte infusion. Unfortunately, donor lymphocyte infusion induced severe cortisone-resistant gastrointestinal graft-versus-host disease, and the patient died from multiple organ failure 4 months after transplantation. The girl is doing well 33 months after transplantation, and clinically, all signs of SLE have resolved. CONCLUSIONS: Allo-HSCT can cure SLE in human C1q deficiency and should be considered early in subjects resistant to medical therapy.
Authors: Rosanne A van Schaarenburg; César Magro-Checa; Jaap A Bakker; Y K Onno Teng; Ingeborg M Bajema; Tom W Huizinga; Gerda M Steup-Beekman; Leendert A Trouw Journal: Front Immunol Date: 2016-12-27 Impact factor: 7.561
Authors: Milica Zecevic; Aleksandra Minic; Srdjan Pasic; Vladimir Perovic; Zoltán Prohászka Journal: Front Pediatr Date: 2021-12-21 Impact factor: 3.418
Authors: Nicholas Brodszki; Ashley Frazer-Abel; Anete S Grumach; Michael Kirschfink; Jiri Litzman; Elena Perez; Mikko R J Seppänen; Kathleen E Sullivan; Stephen Jolles Journal: J Clin Immunol Date: 2020-02-17 Impact factor: 8.317
Authors: Alice Y Chan; Jennifer W Leiding; Xuerong Liu; Brent R Logan; Lauri M Burroughs; Eric J Allenspach; Suzanne Skoda-Smith; Gulbu Uzel; Luigi D Notarangelo; Mary Slatter; Andrew R Gennery; Angela R Smith; Sung-Yun Pai; Michael B Jordan; Rebecca A Marsh; Morton J Cowan; Christopher C Dvorak; John A Craddock; Susan E Prockop; Shanmuganathan Chandrakasan; Neena Kapoor; Rebecca H Buckley; Suhag Parikh; Deepak Chellapandian; Benjamin R Oshrine; Jeffrey J Bednarski; Megan A Cooper; Shalini Shenoy; Blachy J Davila Saldana; Lisa R Forbes; Caridad Martinez; Elie Haddad; David C Shyr; Karin Chen; Kathleen E Sullivan; Jennifer Heimall; Nicola Wright; Monica Bhatia; Geoffrey D E Cuvelier; Frederick D Goldman; Isabelle Meyts; Holly K Miller; Markus G Seidel; Mark T Vander Lugt; Rosa Bacchetta; Katja G Weinacht; Jeffrey R Andolina; Emi Caywood; Hey Chong; Maria Teresa de la Morena; Victor M Aquino; Evan Shereck; Jolan E Walter; Morna J Dorsey; Christine M Seroogy; Linda M Griffith; Donald B Kohn; Jennifer M Puck; Michael A Pulsipher; Troy R Torgerson Journal: Front Immunol Date: 2020-02-21 Impact factor: 7.561